Background: There are limited data on the use and concern of telemedicine among German urologists, and thus, there are no established guidelines for telemedical diagnosis, treatment, and prevention of urological indications. Methods: An anonymized survey was conducted among German private practice urologists during the 2019 coronavirus disease (COVID-19) pandemic. The χ2 test, Mann-Whitney U-test, and Kruskal-Wallis test were used for statistical analysis. Results: 257 urologists were included in the final analysis. Thirty-five (14.0%) of urologists had used telemedicine as part of their consultation, and 221 (86.0%) had not used telemedicine. There was no difference between telemedicine adoption rates between rural and urban settings. Telemedicine users were significantly more satisfied with the information they had received regarding telemedicine issues. Users saw the greatest barrier to telemedicine that patients do not take up the offer of telemedicine. Nonusers were most concerned with unclear indications for telemedicine followed by lesser reimbursements during telemedicine than in-person visitations. Users were significantly more likely to use telemedicine beyond the COVID-19 pandemic. Urologists, who wanted to use the service in the future, wanted an active support by the German society of urology and guidelines for telemedicine. Last, users and nonusers preferred telemedicine for non-acute chronic diseases and follow-up visitations. Conclusion: Despite the COVID-19 pandemic, telemedicine remains a rarely used service among German private practice urologists. Ultimately, to overcome the current challenges, urologists require an active support for the service through the German Society of Urology and telemedical guidelines.

1.
Hollander
JE
,
Carr
BG
.
Virtually Perfect? Telemedicine for Covid-19
.
N Engl J Med
.
2020 Apr 30
;
382
(
18
):
1679
1681
.
2.
Tuckson
RV
,
Edmunds
M
,
Hodgkins
ML
.
Telehealth
.
N Engl J Med
.
2017
;
377
(
16
):
1585
92
. .
3.
Puskin
DS
.
Opportunities and challenges to telemedicine in rural America
.
J Med Syst
.
1995
;
19
(
1
):
59
67
. .
4.
Alverson
DC
,
Shannon
S
,
Sullivan
E
,
Prill
A
,
Effertz
G
,
Helitzer
D
, et al.
Telehealth in the trenches: reporting back from the frontlines in rural America
.
Telemed J E Health
.
2004
;
10
(
Suppl 2
):
S
109
. .
5.
Scott
AC
,
McDonald
A
,
Roberts
T
,
Martin
C
,
Manns
T
,
Webster
M
, et al.
Cardiovascular telemedicine program in rural Australia
.
N Engl J Med
.
2020
;
383
(
9
):
883
4
. .
7.
European Comission. Benchmarking Deployment of eHealth among General Practitioners (2018). https://ec.europa.eu/digital-single-market/en/news/ehealth-adoption-primary-healthcare-eu-rise. Access on December 22nd, 2020. Accessed.
8.
Ellimoottil
C
,
Skolarus
T
,
Gettman
M
,
Boxer
R
,
Kutikov
A
,
Lee
BR
, et al.
Telemedicine in urology: state of the art
.
Urology
.
2016
;
94
:
10
6
. .
9.
Privatewaterhouse Coopers (PWC) EU Services: European Hospital Survey: Benchmarking Deployment of e-Health Services (2012–2013). in JRC Scientific and Policy Reports. 2014.
10.
Brauns
H-J
,
Loos
W
.
Telemedizin in Deutschland
.
Bundesgesundheitsbl.
2015
;
58
(
10
):
1068
73
. .
11.
Liang
W
,
Guan
W
,
Chen
R
,
Wang
W
,
Li
J
,
Xu
K
, et al.
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
.
Lancet Oncol
.
2020
;
21
(
3
):
335
7
. .
12.
Rodler
S
,
Apfelbeck
M
,
Schulz
GB
,
Ivanova
T
,
Buchner
A
,
Staehler
M
, et al.
Telehealth in uro-oncology beyond the pandemic: toll or lifesaver?
Eur Urol Focus
.
2020 Sep 15
;
6
(
5
):
1097
103
.
13.
Novara
G
,
Checcucci
E
,
Crestani
A
,
Abrate
A
,
Esperto
F
,
Pavan
N
, et al.
Telehealth in urology: a systematic review of the literature. how much can telemedicine be useful during and after the COVID-19 pandemic?
Eur Urol
.
2020 Dec
;
78
(
6
):
786
811
.
14.
Ribal
MJ
,
Cornford
P
,
Briganti
A
,
Knoll
T
,
Gravas
S
,
Babjuk
M
, et al.
European association of urology guidelines office rapid reaction group: an organisation-wide collaborative effort to adapt the european association of urology guidelines recommendations to the coronavirus disease 2019 era
.
Eur Urol
.
2020
;
78
(
1
):
21
8
. .
15.
Bundesärztekammer
.
Ärztestatistik zum 31. Dezember 2019 [accessed 2020
.
Nov
5]. Available from:
https://www.bundesaerztekammer.de/fileadmin/user_upload/downloads/pdf-Ordner/Statistik2019/Stat19AbbTab.pdf.
16.
Obermann
M
.
Ärzte im Zukunftsmarkt Gesundheit 2017
.
2017
.
17.
Obermann
B
,
Müller
S
.
Ärzte im Zukunftsmarkt Gesundheit 2020: Ärztliche Arbeit und Nutzung von Videosprechstunden während der Covid-19-Pandemie
.
2020
.
18.
Paffenholz
P
,
Peine
A
,
Fischer
N
,
Hellmich
M
,
Pfister
D
,
Heidenreich
A
, et al.
Impact of the COVID-19 pandemic on urologists in Germany
.
Eur Urol Focus
.
2020
;
6
(
5
):
1111
9
. .
19.
Lakshin
G
,
Banek
S
,
Keese
D
,
Rolle
U
,
Schmedding
A
.
Telemedicine in the pediatric surgery in Germany during the COVID-19 pandemic
.
Pediatr Surg Int
.
2021
;
37
(
3
):
389
95
. .
20.
Bundesamt für Statistik: Internetnutzung von Personen nach Altersgruppen in %. https://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Einkommen-Konsum-Lebensbedingungen/_Grafik/_Interaktiv/it-nutzung-alter.html (last accessed on 02.11.2020). Accessed.
21.
Rodler
S
,
Buchner
A
,
Stief
CG
,
Heinemann
V
,
Staehler
M
,
Casuscelli
J
.
Patients´ perspective on digital technologies in advanced genitourinary cancers
.
Clin Genitourin Cancer
.
2021 Feb
;
19
(
1
):
76
82.e6
.
22.
Australian College of Rural and Remote Medicine
.
ACRRM Telehealth Guidelines
.
2016
.
23.
Krupinski
EA
,
Bernard
J
.
Standards and guidelines in telemedicine and telehealth
.
Healthcare
.
2014
;
2
(
1
):
74
93
. .
24.
Gough
F
,
Budhrani
S
,
Cohn
E
,
Dappen
A
,
Leenknecht
C
,
Lewis
B
, et al.
ATA practice guidelines for live, on-demand primary and urgent care
.
Telemed J E Health
.
2015
;
21
(
3
):
233
41
. .
25.
Rodriguez Socarrás
M
,
Loeb
S
,
Teoh
JY-C
,
Ribal
MJ
,
Bloemberg
J
,
Catto
J
, et al.
Telemedicine and Smart Working: recommendations of the European association of urology
.
Eur Urol
.
2020
;
78
(
6
):
812
9
. .
26.
Gadzinski
AJ
,
Ellimoottil
C
.
Telehealth in urology after the COVID-19 pandemic
.
Nat Rev Urol
.
2020
;
17
(
7
):
363
4
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.